| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
Correspondence to: Theodore E. Warkentin, MD, Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, General Site, 237 Barton St E, Hamilton, Ontario L8L 2X2, Canada; e-mail: twarken{at}mcmaster.ca
This chapter about the recognition, treatment, and prevention of heparin-induced thrombocytopenia (HIT) is part of the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients’ values may lead to different choices (for a full understanding of the grading, see Guyatt et al, CHEST 2004; 126:179S–187S). Among the key recommendations in this chapter are the following: For patients in whom the risk of HIT is considered to be > 0.1%, we recommend platelet count monitoring (Grade 1C). For patients who are receiving therapeutic-dose unfractionated heparin (UFH), we suggest at least every-other-day platelet count monitoring until day 14, or until UFH is stopped, whichever occurs first (Grade 2C). For patients who are receiving postoperative antithrombotic prophylaxis with UFH (HIT risk > 1%), we suggest at least every-other-day platelet count monitoring between postoperative days 4 to 14 (or until UFH is stopped, whichever occurs first) [Grade 2C]. For medical/obstetric patients who are receiving prophylactic-dose UFH, postoperative patients receiving prophylactic-dose low molecular weight heparin (LMWH), postoperative patients receiving intravascular catheter UFH "flushes," or medical/obstetrical patients receiving LMWH after first receiving UFH (risk, 0.1 to 1%), we suggest platelet count monitoring every 2 days or 3 days from day 4 to day 14, or until heparin is stopped, whichever occurs first (Grade 2C). For medical/obstetrical patients who are only receiving LMWH, or medical patients who are receiving only intravascular catheter UFH flushes (risk < 0.1%), we suggest clinicians do not use routine platelet count monitoring (Grade 2C). For patients with strongly suspected (or confirmed) HIT, whether or not complicated by thrombosis, we recommend use of an alternative anticoagulant, such as lepirudin (Grade 1C+), argatroban (Grade 1C), bivalirudin (Grade 2C), or danaparoid (Grade 1B). For patients with strongly suspected (or confirmed) HIT, we recommend routine ultrasonography of the lower-limb veins for investigation of deep venous thrombosis (Grade 1C); against the use of vitamin K antagonist (VKA) [coumarin] therapy until after the platelet count has substantially recovered; that the VKA antagonist be administered only during overlapping alternative anticoagulation (minimum 5-day overlap); and begun with low, maintenance doses (all Grade 1C). For patients receiving VKAs at the time of diagnosis of HIT, we recommend use of vitamin K (Grade 2C). For patients with a history of HIT who are HIT antibody negative and require cardiac surgery, we recommend use of UFH (Grade 1C). [Editor's note: These Grades have been changed as an erratum to the original printed version of this article.]
Key Words: antithrombotic • heparin • prophylaxis • thrombocytopenia
This article has been cited by other articles:
|
|
 |
|
  J. M. Walenga, A. F. Drenth, M. Mayuga, D. A. Hoppensteadt, M. Prechel, S. Harder, H. Watanabe, M. Osakabe, and H.-K. Breddin Transition From Argatroban to Oral Anticoagulation With Phenprocoumon or Acenocoumarol: Effect on Coagulation Factor Testing Clinical and Applied Thrombosis/Hemostasis, July 1, 2008; 14(3): 325 - 331. [Abstract] [PDF]
|
|
|
|
 |
|
 V. F. Tapson, H. Decousus, M. Pini, B. H. Chong, J. B. Froehlich, M. Monreal, A. C. Spyropoulos, G. J. Merli, R. B. Zotz, J.-F. Bergmann, et al. Venous Thromboembolism Prophylaxis in Acutely Ill Hospitalized Medical Patients: Findings From the International Medical Prevention Registry on Venous Thromboembolism Chest, September 1, 2007; 132(3): 936 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gozdzikiewicz, J. Borawski, and M. Mysliwiec Treatment of Heparin-Induced Thrombocytopenia Type II in Hemodialysis Patients: The Search for a Holy Grail Continues Clinical and Applied Thrombosis/Hemostasis, January 1, 2007; 13(1): 110 - 111. [PDF]
|
|
|
|
 |
|
 T. E. Warkentin, J.-A. I. Sheppard, C. S. Sigouin, T. Kohlmann, P. Eichler, and A. Greinacher Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia Blood, November 1, 2006; 108(9): 2937 - 2941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Greinacher, M. Gopinadhan, J.-U. Gunther, M. A. Omer-Adam, U. Strobel, T. E. Warkentin, G. Papastavrou, W. Weitschies, and C. A. Helm Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT Antibodies Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2386 - 2393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Levine, D. McCollum, and M. J. Hursting How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia? Chest, September 1, 2006; 130(3): 681 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A Nutescu, A. K Wittkowsky, P. P Dobesh, D. W Hawkins, and W. E Dager Choosing the Appropriate Antithrombotic Agent for the Prevention and Treatment of VTE: A Case-Based Approach Ann. Pharmacother., September 1, 2006; 40(9): 1558 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Arepally and T. E. Warkentin Lepirudin: walking the dosing line Blood, September 1, 2006; 108(5): 1428 - 1429. [Full Text] [PDF]
|
|
|
|
|
|
L. E Efird and D. R Kockler Fondaparinux for Thromboembolic Treatment and Prophylaxis of Heparin-Induced Thrombocytopenia Ann. Pharmacother., July 1, 2006; 40(7): 1383 - 1387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Warkentin Thrombotic End Point for Assessing Argatroban Therapy for Heparin-Induced Thrombocytopenia: Learning From Secondary Analyses of Prospective Studies Chest, June 1, 2006; 129(6): 1396 - 1398. [Full Text] [PDF]
|
|
|
|
|
|
B. E. Lewis, D. E. Wallis, M. J. Hursting, R. L. Levine, and F. Leya Effects of Argatroban Therapy, Demographic Variables, and Platelet Count on Thrombotic Risks in Heparin-Induced Thrombocytopenia Chest, June 1, 2006; 129(6): 1407 - 1416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. de Maistre, Y. Gruel, and D. Lasne Diagnosis and management of heparin-induced thrombocytopenia: [Le diagnostic et le traitement de la thrombopenie induite par l'heparine]. Can J Anesth, June 1, 2006; 53(6_suppl): S123 - S134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Levine, M. J. Hursting, and D. McCollum Argatroban Therapy in Heparin-Induced Thrombocytopenia With Hepatic Dysfunction Chest, May 1, 2006; 129(5): 1167 - 1175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kodityal, P. H. Nguyen, A. Kodityal, J. Sherer, M. J. Hursting, and L. Rice Argatroban for Suspected Heparin-Induced Thrombocytopenia: Contemporary Experience at a Large Teaching Hospital J Intensive Care Med, March 1, 2006; 21(2): 86 - 92. [Abstract] [PDF]
|
|
|
|
 |
|
 A. K. Lilikakis, T. Papapolychroniou, G. Macheras, and E. Michelinakis Thrombocytopenia and Intra-cerebral Complications Associated with Low-Molecular-Weight Heparin Treatment in Patients Undergoing Total Hip Replacement. A Report of Two Cases J. Bone Joint Surg. Am., March 1, 2006; 88(3): 634 - 638. [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Sacco, R. Adams, G. Albers, M. J. Alberts, O. Benavente, K. Furie, L. B. Goldstein, P. Gorelick, J. Halperin, R. Harbaugh, et al. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Stroke, February 1, 2006; 37(2): 577 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W Finks Bivalirudin Use in Carotid Endarterectomy in a Patient with Heparin-Induced Thrombocytopenia Ann. Pharmacother., February 1, 2006; 40(2): 340 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Marymont, G. S. Murphy, and H. C. Gilbert Intraoperative heparin and heparin-induced thrombocytopenia. Anesth. Analg., January 1, 2006; 102(1): 328 - 328. [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Antonijevic, R. Milosevic, J. Perunicic, M. Stanojevic, B. Calija, and Z. Vasiljevic Need for more intensive treatment of patients with acute pulmonary embolism caused by heparin-induced thrombocytopaenia Type II Eur. Heart J., December 2, 2005; 26(24): 2745 - 2746. [Full Text] [PDF]
|
|
|
|
|
|
M. Wasowicz, A. Vegas, M. A. Borger, and S. Harwood Bivalirudin anticoagulation for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia: [L'anticoagulation avec la bivalirudine pour la circulation extracorporelle chez un patient atteint de thrombocytopenie immunitaire a l'heparine (TIH)] Can J Anesth, December 1, 2005; 52(10): 1093 - 1098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kopterides What Is the Appropriate Anticoagulation Therapy in Patients with a History of Heparin-Induced Thrombocytopenia? Anesth. Analg., December 1, 2005; 101(6): 1885 - 1885. [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin, R. J. Cook, V. J. Marder, J.-A. I. Sheppard, J. C. Moore, B. I. Eriksson, A. Greinacher, and J. G. Kelton Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin Blood, December 1, 2005; 106(12): 3791 - 3796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin and A. Greinacher Unfractionated LMWH and the risk of HIT: are medical patients different? Blood, November 1, 2005; 106(9): 2931 - 2932. [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin HIT as a preventable disease? Blood, October 15, 2005; 106(8): 2600 - 2600. [Full Text] [PDF]
|
|
|
|
|
|
H. L. Messmore Jr, J. Fareed, J. M. Walenga, and R. L. Bick Argatroban and Lepirudin: Clinical Trials to Clinical Practice Clinical and Applied Thrombosis/Hemostasis, October 1, 2005; 11(4): 367 - 369. [PDF]
|
|
|
|
|
|
B. V Reddy, E. J Grossman, S. A Trevino, M. J Hursting, and P. T Murray Argatroban Anticoagulation in Patients with Heparin-Induced Thrombocytopenia Requiring Renal Replacement Therapy Ann. Pharmacother., October 1, 2005; 39(10): 1601 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Di Nisio, S. Middeldorp, and H. R. Buller Direct Thrombin Inhibitors N. Engl. J. Med., September 8, 2005; 353(10): 1028 - 1040. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Hursting, B. E. Lewis, and D. E. Macfarlane Transitioning from Argatroban to Warfarin Therapy in Patients with Heparin-induced Thrombocytopenia Clinical and Applied Thrombosis/Hemostasis, July 1, 2005; 11(3): 279 - 287. [Abstract] [PDF]
|
|
|
|
 |
|
 I.-K. Jang and M. J. Hursting When Heparins Promote Thrombosis: Review of Heparin-Induced Thrombocytopenia Circulation, May 24, 2005; 111(20): 2671 - 2683. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Verme-Gibboney, J. W. Dubb, S. A. Spinler, and A. Greinacher Direct thrombin inhibitors in heparin-induced thrombocytopenia Am. J. Health Syst. Pharm., February 1, 2005; 62(3): 247 - 250. [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin Heparin-Induced Thrombocytopenia: Diagnosis and Management Circulation, November 2, 2004; 110(18): e454 - e458. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
